ADIPOQ and type 2 diabetes mellitus: There is an accumulating body of evidence demonstrating that hypoadiponectinaemia is associated with the development of insulin resistance, type 2 diabetes and metabolic syndrome and that adiponectin may be considered as a surrogate marker for atherosclerosis and CV risk [27, 28].